AOD-9604: Chemical Properties
21 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: abril de 2026
Propriedades Quimicas
| Formula | C78H123N23O23S2 |
| Molecular Weight | 1815.1 g/mol |
| Synonyms | AOD9604, Tyr-hGH Frag 176-191 |
| Cas Number | 221231-10-3 |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Disulfide bridge: Cys7-Cys14) |
| Pubchem Cid | 16131447 |
| Monoisotopic Mass | 1813.86035961 |
| Polar Area | 815 Ų |
| Complexity | 3710 |
| X Log P | -4.8 |
| Heavy Atom Count | 126 |
| H Bond Donor Count | 28 |
| H Bond Acceptor Count | 28 |
| Rotatable Bond Count | 45 |
Identificadores
| Pubchem Cid | 16131447 |
| Inchi | InChI=1S/C78H123N23O23S2/c1-9-41(8)62(101-68(115)47(18-14-28-56-78(83)84)91-69(116)50(29-38(2)3)95-63(110)45(79)30-43-19-21-44(104)22-20-43)75(122)100-61(40(6)7)74(121)94-49(23-25-56(80)105)67(114)98-55-37-126-125-36-54(65(112)88-32-57(106)89-51(76(123)124)31-42-15-11-10-12-16-42)97-70(117)52(34-102)90-58(107)33-87-64(111)48(24-26-59(108)109)93-73(120)60(39(4)5)99-71(118)53(35-103)96-66(113)46(92-72(55)119)17-13-27-85-77(81)82/h10-12,15-16,19-22,38-41,45-55,60-62,102-104H,9,13-14,17-18,23-37,79H2,1-8H3 |
| Inchi Key | GVIYUKXRXPXMQM-BPXGDYAESA-N |
| Smiles Isometric | CC[C@H](C)[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CCCNC(=N)N)C0)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N |
| Smiles Canonical | CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC1CSSCC(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCCNC(=N)N)CO)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)O) |
| Iupac Name | (2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid |
Referencias
- Heffernan, M., et al. (2001). The effects of human GH e seu(sua) lipolytic fragment (AOD9604) on lipid metabolismo apos cronico(a) aplicacao em pesquisa in camundongos obesos and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182-5189.
- Ng, F. M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human hormonio do crescimento. Hormone Research, 53(6), 274-278.
- Ng, F. M. & Bornstein, J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human hormonio do crescimento. Am J Physiol, 235(1), E55-E59.
- Ng, F. M., et al. (2000). Molecular and cellular actions of a structural domain of human hormonio do crescimento (AOD9401) on lipid metabolismo in Zucker fatty rats. J Mol Endocrinol, 25(3), 287-298.
- Kwon, D. R. & Park, G. Y. (2015). Effect of Intra-articular Injection of AOD9604 with or sem Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci, 45(4), 426-432.
- Kwon, D. R., et al. (2020). Regenerative effects of intra-articular injection of AOD 9604 combined with hyaluronic acid in a modelo de coelho of collagenase-induziu osteoartrite. compound Des Devel Ther, 14, 2193-2201.
- Lateral Pharma Pty Ltd. (2020). LAT8881 (AOD9604) host-protective protocolo experimental for influenza A virus infection. Clinical development update.
- Wu, Z., et al. (1993). The structural determinants do(a) lipolytic fragment (residues 177-191) of human hormonio do crescimento. Int J Pept Protein Res, 41(5), 432-438.
- Ng, F. M., et al. (1990). Action of a synthetic lipotropic peptide of human hormonio do crescimento on lipogenesis in rats. J Mol Endocrinol, 5(3), 265-271.
- Heffernan, M., et al. (2000). The effects of AOD9604 on beta-3 adrenergic receptor expression and lipolysis in camundongos obesos. Obesity Research, 8(S1), abstract.
- Groenewegen, W. A., et al. (2004). Oral AOD9604 reduz body fat in Zucker rats by selective massa gorda reduction sem effect on massa corporal magra. Appetite, 42(3), abstract.
- Ng, F. M. & Roupas, P. (1999). Anti-lipogenic action do(a) C-terminal fragment 177-191 of human hormonio do crescimento. Res Commun Mol Pathol Pharmacol, 106(1-2), 35-48.
- Tomer, Y. & Bhargava, A. S. (1999). Growth hormone receptor and signal transduction. In: Molecular Biology of Growth Hormone Receptors. Springer.
- Wu, Z., et al. (1994). Mapping a funcaoal domains of human hormonio do crescimento necessario(a) para metabolic activity. J Biol Chem, 269(22), 15523-15530.
- Stier, H., et al. (2013). tolerability and Tolerability do(a) Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab, 3(1-2), 7-15.
- Metabolic Pharmaceuticals Limited. (2007). Metabolic’s obesidade compound – Phase 2B ensaio clinico results. ASX Announcement, 27 June 2007.
- Thompson, G., et al. (2004). Phase 2b ensaio clinico results for AOD9604. Presented no(a) International Congress on Obesity.
- Kwon, D. R., et al. (2019). Regenerative effects of AOD9604 with or sem hyaluronic acid on tendon healing in a rat Achilles tendon injury model. compound Des Devel Ther, 13, 4173-4186.
- Stier, H. & Kenley, D. (2012). Preclinical and clinical tolerability review of AOD9604. Regul Toxicol Pharmacol, 64(2), S34-S35.
- U.S. Food and Drug Administration. (2023). Substancia Farmaceutica a Granels Used in Compounding Under Section 503B. FDA.gov.
- World Anti-Doping Agency. (2024). The Lista de Substancias Proibidas: International Standard. Section S2.
Perguntas de Pesquisa Relacionadas
Deseja a revisao completa da pesquisa?
Ver Pagina Completa de Pesquisa de AOD-9604→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.